154 related articles for article (PubMed ID: 31204866)
21. Tenofovir diphosphate levels in dried blood spots are associated with virologic failure and resistance to first-line therapy in South Africa: a case-control cohort study.
Castillo-Mancilla JR; Edwards JA; Brijkumar J; Moosa MY; Zhao Y; Ofotokun I; Johnson BA; Lee MH; Pillay S; Pillay M; Moodley P; Kuritzkes DR; Sunpath H; Bushman LR; Ellison L; Anderson PL; Marconi VC
J Int AIDS Soc; 2021 Dec; 24(12):e25849. PubMed ID: 34910844
[TBL] [Abstract][Full Text] [Related]
22. Stable Caloric Intake and Continued Virologic Suppression for HIV-Positive Antiretroviral Treatment-Experienced Women After Switching to a Single-Tablet Regimen of Emtricitabine, Rilpivirine, and Tenofovir Disoproxil Fumarate.
Menezes P; Mollan K; Hoffman E; Xie Z; Wills J; Marcus C; Rublein J; Hudgens M; Eron JJ
AIDS Res Hum Retroviruses; 2018 Jun; 34(6):481-485. PubMed ID: 29607652
[TBL] [Abstract][Full Text] [Related]
23. Simplification of antiretroviral therapy to a single-tablet regimen consisting of efavirenz, emtricitabine, and tenofovir disoproxil fumarate versus unmodified antiretroviral therapy in virologically suppressed HIV-1-infected patients.
Dejesus E; Young B; Morales-Ramirez JO; Sloan L; Ward DJ; Flaherty JF; Ebrahimi R; Maa JF; Reilly K; Ecker J; McColl D; Seekins D; Farajallah A;
J Acquir Immune Defic Syndr; 2009 Jun; 51(2):163-74. PubMed ID: 19357529
[TBL] [Abstract][Full Text] [Related]
24. Patient-reported outcomes in the single-tablet regimen (STaR) trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate in antiretroviral treatment-naive adults infected with HIV-1 through 48 weeks of treatment.
Wilkins EL; Cohen CJ; Trottier B; Esser S; Smith DE; Haas B; Brinson C; Garner W; Chuck S; Thorpe D; De-Oertel S
AIDS Care; 2016; 28(3):401-8. PubMed ID: 26489045
[TBL] [Abstract][Full Text] [Related]
25. Switching to a rilpivirine/emtricitabine/tenofovir single-tablet regimen in RNA-suppressed patients infected with human immunodeficiency virus 1: Effectiveness, safety and costs at 96 weeks.
Arrabal-Durán P; Rodríguez-González CG; Chamorro-de-Vega E; Gijón-Vidaurreta P; Herranz-Alonso A; Sanjurjo-Sáez M
Int J Clin Pract; 2017 Aug; 71(8):. PubMed ID: 28722790
[TBL] [Abstract][Full Text] [Related]
26. Use of Tenofovir Diphosphate Levels to Predict Viremia During the Postpartum Period in Women Living With Human Immunodeficiency Virus (HIV): A Nested Case-Control Study.
Odayar J; Orrell C; Phillips TK; Hu NC; Kabanda S; Malaba TR; Allerton J; Wiesner L; Hsiao NY; Castillo-Mancilla J; Lesosky M; Myer L
Clin Infect Dis; 2022 Sep; 75(5):761-767. PubMed ID: 34979553
[TBL] [Abstract][Full Text] [Related]
27. Urine assay for tenofovir to monitor adherence in real time to tenofovir disoproxil fumarate/emtricitabine as pre-exposure prophylaxis.
Koenig HC; Mounzer K; Daughtridge GW; Sloan CE; Lalley-Chareczko L; Moorthy GS; Conyngham SC; Zuppa AF; Montaner LJ; Tebas P
HIV Med; 2017 Jul; 18(6):412-418. PubMed ID: 28444867
[TBL] [Abstract][Full Text] [Related]
28. Short communication: Tenofovir diphosphate in dried blood spots as an objective measure of adherence in HIV-infected women.
Castillo-Mancilla JR; Searls K; Caraway P; Zheng JH; Gardner EM; Predhomme J; Bushman LR; Anderson PL; Meditz AL
AIDS Res Hum Retroviruses; 2015 Apr; 31(4):428-32. PubMed ID: 25328112
[TBL] [Abstract][Full Text] [Related]
29. Engagement in Mental Health Care is Associated with Higher Cumulative Drug Exposure and Adherence to Antiretroviral Therapy.
Coyle RP; Schneck CD; Morrow M; Coleman SS; Gardner EM; Zheng JH; Ellison L; Bushman LR; Kiser JJ; Mawhinney S; Anderson PL; Castillo-Mancilla JR
AIDS Behav; 2019 Dec; 23(12):3493-3502. PubMed ID: 30798457
[TBL] [Abstract][Full Text] [Related]
30. Simplification to rilpivirine/emtricitabine/tenofovir disoproxil fumarate from ritonavir-boosted protease inhibitor antiretroviral therapy in a randomized trial of HIV-1 RNA-suppressed participants.
Palella FJ; Fisher M; Tebas P; Gazzard B; Ruane P; Van Lunzen J; Shamblaw D; Flamm J; Ebrahimi R; Porter D; White K; Hindman J; Elbert E; De-Oertel S; Fralich T
AIDS; 2014 Jan; 28(3):335-44. PubMed ID: 24670520
[TBL] [Abstract][Full Text] [Related]
31. Validation of an LC-MS/MS assay to simultaneously monitor the intracellular active metabolites of tenofovir, emtricitabine, and lamivudine in dried blood spots.
Schauer AP; Sykes C; Cottrell ML; Prince H; Kashuba ADM
J Pharm Biomed Anal; 2018 Feb; 149():40-45. PubMed ID: 29100029
[TBL] [Abstract][Full Text] [Related]
32. Tenofovir-Diphosphate in Dried Blood Spots vs Tenofovir in Urine/Plasma for Oral Preexposure Prophylaxis Adherence Monitoring.
Niu X; Kubiak RW; Siriprakaisil O; Klinbuyaem V; Sukrakanchana PO; Cressey R; Okochi H; Gandhi M; Cressey TR; Drain PK
Open Forum Infect Dis; 2022 Aug; 9(8):ofac405. PubMed ID: 36004315
[TBL] [Abstract][Full Text] [Related]
33. Model Linking Plasma and Intracellular Tenofovir/Emtricitabine with Deoxynucleoside Triphosphates.
Chen X; Seifert SM; Castillo-Mancilla JR; Bushman LR; Zheng JH; Kiser JJ; MaWhinney S; Anderson PL
PLoS One; 2016; 11(11):e0165505. PubMed ID: 27832147
[TBL] [Abstract][Full Text] [Related]
34. Concordance between daily diary reported pre-exposure prophylaxis intake and intraerythrocytic tenofovir diphosphate in the Amsterdam Pre-exposure Prophylaxis demonstration project.
Wijstma ES; Jongen VW; Boyd A; van den Elshout MAM; de Vries HJC; Davidovich U; Anderson PL; Prins M; Hoornenborg E; Schim van der Loeff MF
AIDS; 2024 Jul; 38(8):1248-1256. PubMed ID: 38518076
[TBL] [Abstract][Full Text] [Related]
35. Short Communication: A Descriptive Analysis of Dried Blood Spot Adherence Testing Among Ugandans with HIV Presenting with Cryptococcal Meningitis.
Lofgren SM; Nicol MR; Kandole TK; Castillo-Mancilla J; Anderson PL; Mpoza E; Tugume L; Bangdiwala AS; Ssebambulidde K; Hullsiek KH; Rhein J; Meya DB; Boulware DR
AIDS Res Hum Retroviruses; 2021 Jul; 37(7):529-533. PubMed ID: 33677986
[TBL] [Abstract][Full Text] [Related]
36. Urine Tenofovir Concentrations Correlate With Plasma and Relate to Tenofovir Disoproxil Fumarate Adherence: A Randomized, Directly Observed Pharmacokinetic Trial (TARGET Study).
Drain PK; Kubiak RW; Siriprakaisil O; Klinbuayaem V; Quame-Amaglo J; Sukrakanchana PO; Tanasri S; Punyati P; Sirirungsi W; Cressey R; Bacchetti P; Okochi H; Baeten JM; Gandhi M; Cressey TR
Clin Infect Dis; 2020 May; 70(10):2143-2151. PubMed ID: 31314073
[TBL] [Abstract][Full Text] [Related]
37. Short Communication: Association of Vitamin D Insufficiency and Protective Tenofovir Diphosphate Concentrations with Bone Toxicity in Adolescent Boys and Young Men Using Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Pre-Exposure Prophylaxis.
Havens PL; Tamhane A; Stephensen CB; Schuster GU; Gordon CM; Liu N; Wilson CM; Hosek SG; Anderson PL; Kapogiannis BG; Mulligan K
AIDS Res Hum Retroviruses; 2019 Feb; 35(2):123-128. PubMed ID: 30280906
[TBL] [Abstract][Full Text] [Related]
38. Individualized Adherence Benchmarks for HIV Pre-Exposure Prophylaxis.
Ibrahim ME; Castillo-Mancilla JR; Yager J; Brooks KM; Bushman L; Saba L; Kiser JJ; MaWhinney S; Anderson PL
AIDS Res Hum Retroviruses; 2021 Jun; 37(6):421-428. PubMed ID: 33191774
[TBL] [Abstract][Full Text] [Related]
39. Tenofovir diphosphate in dried blood spots predicts future viremia in persons with HIV taking antiretroviral therapy in South Africa.
Jennings L; Robbins RN; Nguyen N; Ferraris C; Leu CS; Dolezal C; Hsiao NY; Mgbako O; Joska J; Castillo-Mancilla JR; Myer L; Anderson PL; Remien RH; Orrell C;
AIDS; 2022 Jun; 36(7):933-940. PubMed ID: 35131960
[TBL] [Abstract][Full Text] [Related]
40. Cumulative tenofovir diphosphate exposure in persons with HIV taking single- vs. multiple-tablet regimens.
Coyle RP; Morrow M; MaWhinney S; Coleman SS; Zheng JH; Ellison L; Bushman LR; Kiser JJ; Anderson PL; Castillo-Mancilla JR
Pharmacotherapy; 2022 Aug; 42(8):641-650. PubMed ID: 35707973
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
